Trials / Completed
CompletedNCT06329284
Midkine Role With Deregulated Oxidative and Immune Milieu in Induction of Preeclampsia
Midkine Interplays With Oxidative Stress and Inflammatory Milieu to Induce Preeclampsia in Normotensive Pregnant Women
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- Female
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Preeclampsia (PE) is a hypertensive pregnancy-related disorder that endangers maternal and fetal outcomes and accounts for 9-10% of maternal mortalities with its early-onset phenotype is the most dangerous, but its etiology is still not fully elucidated. Midkine (MDK) is a multifunctional protein that plays a unique role in the development of hypertension (HTN), via its proatherogenic effect and induction of overexpression of angiotensin converting enzyme. Oxidative stress (OS) upregulates the expression of MDK and MDK induces propagation of neoangiogenesis and acts as chemotactic for neutrophils.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ELISA | ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1 |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2023-09-15
- Completion
- 2023-12-15
- First posted
- 2024-03-25
- Last updated
- 2024-03-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06329284. Inclusion in this directory is not an endorsement.